The PASI 90 rate, which is in line with the phase 2 result, looks competitive. Cross-trial comparisons can be unreliable, ...

The drug programs left behind after Jazz Pharmaceuticals' $820 million acquisition of Actio Biosciences have found a new home ...

Eli Lilly’s triple-G drug candidate retatrutide has beaten Novo’s Ozempic in a head-to-head phase 3 trial, driving deeper ...

Eli Lilly has dropped its phase 2 Alzheimer's disease program for mevidalen, marking another setback for the experimental ...

“If Powerful AI is directed at solving humanity’s hardest problems and the risks are managed responsibly, the potential is ...

With the U.S. patent on the immunology megablockbuster Dupixent set to expire in 2031, time is running out for Sanofi to find ...

GSK’s global restructuring plan is likely to see “some limited impact” on roles in the Big Pharma’s home turf of the U.K., ...

BioMarin is paying $70 million upfront to license a Fabry disease drug candidate, expanding the franchise it acquired through ...

Flagship Pioneering unveiled Etcelera today, a new AI-powered biotech emerging from stealth that aims to predict how potential medicines will act in patients.

Every ESMO conference is eventful, but the drama kicked into gear earlier than expected this year when the eagerly ...

Audax sees the propensity for IL-12 drugs to bind receptors on peripheral immune cells as a driver of the dosing and toxicity ...

Bristol Myers Squibb has scrapped a phase 1 program it licensed from Prothena for $80 million. | Bristol Myers Squibb has ...